- Stocks
- Healthcare
- NASDAQ: RGEN

Price (delayed)

$307.37

Market cap

$16.9B

P/E Ratio

166.15

Dividend/share

N/A

EPS

$1.85

Enterprise value

$16.47B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in

RGEN's gross profit has soared by 74% YoY and by 20% QoQ

The revenue has soared by 68% YoY and by 17% from the previous quarter

RGEN's quick ratio has dropped by 82% year-on-year

The stock's P/E is 31% above its 5-year quarterly average of 126.9 and 14% above its last 4 quarters average of 146.1

What are the main financial stats of RGEN

Market
Valuations
Earnings

Shares outstanding

54.98M

Market cap

$16.9B

Enterprise value

$16.47B

Price to earnings (P/E)

166.15

Price to book (P/B)

10.53

Price to sales (P/S)

33.2

EV/EBIT

134.57

EV/EBITDA

106.94

EV/Sales

32.39

Revenue

$508.51M

EBIT

$122.39M

EBITDA

$154.01M

Free cash flow

$40.18M

Per share
Balance sheet
Liquidity

EPS

$1.85

Free cash flow per share

$0.73

Book value per share

$29.2

Revenue per share

$9.26

TBVPS

$20.42

Total assets

$2.02B

Total liabilities

$412.9M

Debt

$305.99M

Equity

$1.6B

Working capital

$651.49M

Debt to equity

0.19

Current ratio

2.96

Quick ratio

2.52

Net debt/EBITDA

-2.78

Margins
Efficiency
Dividend

EBITDA margin

30.3%

Gross margin

58.8%

Net margin

19.7%

Operating margin

24.2%

Return on assets

5.5%

Return on equity

6.9%

Return on invested capital

36.9%

Return on capital employed

7.3%

Return on sales

24.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Repligen stock price performed over time

Intraday

-4.92%

1 week

0.43%

1 month

11.43%

1 year

113.01%

YTD

60.4%

QTD

53.98%

How have Repligen's revenue and profit performed over time

Revenue

$508.51M

Gross profit

$298.98M

Operating income

$123M

Net income

$99.93M

Gross margin

58.8%

Net margin

19.7%

The operating income has soared by 172% YoY and by 30% from the previous quarter

The net margin has soared by 93% YoY and by 7% from the previous quarter

RGEN's gross profit has soared by 74% YoY and by 20% QoQ

The revenue has soared by 68% YoY and by 17% from the previous quarter

What is Repligen's growth rate over time

What is Repligen stock price valuation

P/E

166.15

P/B

10.53

P/S

33.2

EV/EBIT

134.57

EV/EBITDA

106.94

EV/Sales

32.39

The stock's P/E is 31% above its 5-year quarterly average of 126.9 and 14% above its last 4 quarters average of 146.1

RGEN's EPS is up by 24% since the previous quarter

The P/B is 111% more than the 5-year quarterly average of 5.0 and 55% more than the last 4 quarters average of 6.8

Repligen's equity has increased by 46% YoY and by 3% QoQ

RGEN's P/S is 113% above its 5-year quarterly average of 15.6 and 37% above its last 4 quarters average of 24.3

The revenue has soared by 68% YoY and by 17% from the previous quarter

How efficient is Repligen business performance

RGEN's ROA has soared by 150% year-on-year and by 17% since the previous quarter

The return on equity has surged by 138% year-on-year and by 15% since the previous quarter

RGEN's return on sales has surged by 64% year-on-year and by 11% since the previous quarter

The ROIC has grown by 37% from the previous quarter

What is RGEN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RGEN.

How did Repligen financials performed over time

RGEN's quick ratio has dropped by 82% year-on-year

Repligen's current ratio has shrunk by 81% YoY

The debt is 81% less than the equity

Repligen's equity has increased by 46% YoY and by 3% QoQ

Repligen's debt to equity has decreased by 21% YoY but it has increased by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.